Skip to content
Ibumix
  • Technology
    • Bioavailability
    • The tablet problem
    • Lipid & liquid-crystal delivery
    • GRAS & established materials
    • TECHNOLOGY – The Ibumix™ Platform
    • Science and data
    • The Structural Problem Behind Poor Drug Solubility
    • Products
    • Drug-delivery and formulation glossary
  • Company
    • About Ibumix
    • Investor overview
    • Newsroom
    • Connect
  • Insights
Ibumix
  • Technology
    • Bioavailability
    • The tablet problem
    • Lipid & liquid-crystal delivery
    • GRAS & established materials
    • TECHNOLOGY – The Ibumix™ Platform
    • Science and data
    • The Structural Problem Behind Poor Drug Solubility
    • Products
    • Drug-delivery and formulation glossary
  • Company
    • About Ibumix
    • Investor overview
    • Newsroom
    • Connect
  • Insights
21 July 202612 August 2026TechnologyBy George Forrest

The Second Battle, Opened From the Inside

The Second Battle, Opened From the Inside Octreotide, acromegaly and the tight-junction trick that takes on the gut wall directly Rybelsus proved […]

Read more
13 July 202627 August 2026TechnologyBy George Forrest

The Diversification Bet

Eli Lilly has committed more than $20 billion to ten acquisitions in six months, not one of them a tablet. Ibumix reads the pattern against its own predictions on AI, demographics and delivery.

Read more
10 July 202627 August 2026TechnologyBy George Forrest

The First Battle, Won

The First Battle, Won How SNAC turned semaglutide into a tablet — and why 99% of the dose still never arrives In […]

Read more
8 July 202627 August 2026TechnologyBy George Forrest

The Three Battles Every Oral Peptide Must Win

Semaglutide survives a week in the bloodstream as an injection. As a tablet, it must first survive stomach acid, cross the intestinal wall, and stay active in the blood — three separate battles most peptides never win.

Read more
5 July 20266 July 2026TechnologyBy George Forrest

Why GLP-1 Disappears in Minutes — and Ozempic Doesn’t

Natural GLP-1 lasts about a minute in the body. Semaglutide, built from it, lasts a week. The biology behind Ozempic, Wegovy and Mounjaro.

Read more
30 June 202627 August 2026UncategorisedBy George Forrest

The One Per Cent Problem: Why Peptide Medicines Still Can’t Be Swallowed

Most peptide drugs are destroyed before they’re absorbed. Inside the science, the market and the global stakes of cracking oral peptide bioavailability.

Read more
20 June 20266 September 2026TechnologyBy George Forrest

Who Decided How Big a Tablet Should Be?

The hidden engineering behind every pill you’ve ever taken The size of a tablet feels like a design decision. It isn’t. It […]

Read more
15 June 202615 June 2026TechnologyBy George Forrest

The Most Valuable Data in Pharma Is the Data Nobody Keeps

Negative results are the missing fuel for AI drug discovery. The companies that win will be the ones with the highest failure-capture […]

Read more
9 June 202627 August 2026TechnologyBy George Forrest

The Ordered Liquid: potassium cinnamate, GCC and the liquid crystal beneath Cinnamix

A liquid crystal is a paradox — a fluid that flows like a liquid yet holds internal order like a crystal. Cinnamix […]

Read more
5 June 20266 September 2026TechnologyBy George Forrest

Naproxen: A Case Study in Conservative Formulation

When a superior molecule is held back by its delivery system Naproxen’s long-lasting effect is well known. Its slow start is the […]

Read more

Posts pagination

< 1 2 3 … 5 >
© 2026 Ibumix.